1.Early predictors of rescue therapy and colectomy in acute severe ulcerative colitis.
Samuel Jun Ming LIM ; Kaina CHEN ; Yi Yuan TAN ; Shu Wen TAY ; Thomson Chong Teik LIM ; Ennaliza SALAZAR ; Webber Pak-Wo CHAN ; Malcolm Teck Kiang TAN
Singapore medical journal 2025;66(8):449-456
INTRODUCTION:
Acute severe ulcerative colitis (ASUC) is a significant cause of disease morbidity. One-third of patients with ASUC are steroid refractory. Rescue therapy may not successfully induce remission, necessitating colectomy. We aimed to identify predictors of rescue therapy and colectomy in ASUC assessed within 24 h of admission for early risk stratification.
METHODS:
We conducted a retrospective cohort study of 58 admissions for ASUC among 47 patients from August 2002 to January 2022. Serum biomarkers assessed were measured on admission. Primary outcomes were the need for rescue therapy during the same admission and colectomy within 1 year of admission.
RESULTS:
Rescue therapy (all with infliximab) was given in 20 (34.5%) of the admissions. Colectomy was done within 1 year for nine (15.5%) of the admissions. An elevated C-reactive protein (CRP) of >30 mg/L (relative risk [RR] 1.63), a CRP-albumin ratio of >0.85 (RR 1.63), and a composite factor of both CRP > 30 mg/L and age ≥60 years (RR 2.37) were significantly associated with the need for rescue therapy. Hypoalbuminaemia ≤ 25 g/L (RR 4.35) and the use of biologics at presentation (RR 1.54) were significantly associated with colectomy within 1 year of admission, while a CRP of ≥ 80 mg/L was a significant protective factor (RR 0.70).
CONCLUSION
Patients with ASUC who have elevated CRP or CRP-albumin ratio on admission should be considered at risk for steroid-refractory disease. Those with hypoalbuminaemia on admission and using biologics at presentation are more likely to require colectomy in the first year after admission for ASUC.
Humans
;
Colitis, Ulcerative/therapy*
;
Colectomy
;
Retrospective Studies
;
Male
;
Female
;
Middle Aged
;
Adult
;
C-Reactive Protein/metabolism*
;
Infliximab/therapeutic use*
;
Biomarkers/blood*
;
Acute Disease
;
Aged
;
Severity of Illness Index
;
Treatment Outcome
2.Singapore clinical guideline on parenteral nutrition in adult patients in the acute hospital setting.
Johnathan Huey Ming LUM ; Hazel Ee Ling YEONG ; Pauleon Enjiu TAN ; Ennaliza SALAZAR ; Tingfeng LEE ; Yunn Cheng NG ; Janet Ngian Choo CHONG ; Pay Wen YONG ; Jeannie Peng Lan ONG ; Siao Ching GOOI ; Kristie Huirong FAN ; Weihao CHEN ; Mei Yoke LIM ; Kon Voi TAY ; Doris Hui Lan NG
Annals of the Academy of Medicine, Singapore 2025;54(6):350-369
INTRODUCTION:
The primary objective of this guideline is to establish evidence-based recommendations for the clinical use of parenteral nutrition (PN) in adult patients within the acute hospital setting in Singapore.
METHOD:
An expert workgroup, consisting of healthcare practitioners actively involved in clinical nutrition support across all public health institutions, systematically evaluated existing evidence and addressed clinical questions relating to PN therapy.
RESULTS:
This clinical practice guideline developed 30 recommendations for PN therapy, which cover these key aspects related to PN use: indications, patient assess-ment, titration and formulation of PN bags, access routes and devices, and monitoring and management of PN-related complications.
CONCLUSION
This guideline provides recommendations to ensure appropriate and safe clinical practice of PN therapy in adult patients within the acute hospital setting.
Humans
;
Singapore
;
Parenteral Nutrition/adverse effects*
;
Adult

Result Analysis
Print
Save
E-mail